The NK1 antagonist R116301 induces a greater increase in bladder capacity compared to oxybutynin without affecting voiding efficiency
Moreaux B1, Van den Berg J 1, Meulemans A1, Straetemans R 1, Ver Donck L 1, Coulie B1 1. Johnson & Johnson Pharmaceutical Research & Development
Abstract Category
Pharmacology: Basic Science
|
|
Abstract 291
|
|
|
Non Discussion Posters
Scientific Non Discussion Poster Session 17
|
|
|